These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 25327530)

  • 1. Adverse effects of androgen-deprivation therapy in prostate cancer and their management.
    Rhee H; Gunter JH; Heathcote P; Ho K; Stricker P; Corcoran NM; Nelson CC
    BJU Int; 2015 Apr; 115 Suppl 5():3-13. PubMed ID: 25327530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy complications.
    Allan CA; Collins VR; Frydenberg M; McLachlan RI; Matthiesson KL
    Endocr Relat Cancer; 2014 Aug; 21(4):T119-29. PubMed ID: 24872511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG; Canfield SE; Du XL
    Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM; Tran S; Robinson JW
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Patil T; Bernard B
    Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?
    Wibowo E; Wassersug RJ; Robinson JW; Matthew A; McLeod D; Walker LM
    Clin Genitourin Cancer; 2019 Jun; 17(3):e408-e419. PubMed ID: 30745202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.
    Liao KM; Huang YB; Chen CY; Kuo CC
    BMC Cancer; 2019 Dec; 19(1):1263. PubMed ID: 31888558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients and partners lack knowledge of androgen deprivation therapy side effects.
    Walker LM; Tran S; Wassersug RJ; Thomas B; Robinson JW
    Urol Oncol; 2013 Oct; 31(7):1098-105. PubMed ID: 22285008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.